Chiitaranjan Andrade, MD, Associate Professor, Department of Psychopharmacology, NIMHANS, Bangalore - 560 029.
Indian J Psychiatry. 1993 Jul;35(3):179-80.
BR-16A is a herbal preparation with several putative psychotropic effects. Recent work has suggested that it facilities certain aspects of cognition and that it ameliorates ECT-induced amnesia in animal models. The present study sought to assess whether it affects noradrenergic and dopaminergic functioning in the central nervous system. Adult male Sprague-Dawley rats received BR-16A (200mg/kg) or vehicle for one month. The animals were subsequently challenged with clonidine (100 mg/kg I.P.), apomorphine (2mg/kg I.P.), or saline in a factorial design, and motility of the animals was immediately thereafter assessed using a small open field. BR-16A neither attenuated clonidine induced alpha-2 noradrenergic receptor-mediated hypomotility nor accentuated apomorphine-induced dopamine postsynaptic receptor-mediated hypermotility, suggesting that it does not interfere with alpha-2 noradrenergic and dopamine postsynaptic receptor functioning.
BR-16A 是一种具有多种潜在精神活性作用的草药制剂。最近的研究表明，它有助于认知的某些方面，并改善动物模型中的电休克诱导的健忘症。本研究旨在评估它是否影响中枢神经系统中的去甲肾上腺素能和多巴胺能功能。成年雄性 Sprague-Dawley 大鼠接受 BR-16A（200mg/kg）或载体治疗一个月。随后，动物在因子设计中接受可乐定（100mg/kg IP）、阿扑吗啡（2mg/kg IP）或生理盐水的挑战，并且动物的运动性立即使用小的开放场进行评估。BR-16A 既没有减弱可乐定诱导的α-2 去甲肾上腺素能受体介导的低运动性，也没有加重阿扑吗啡诱导的多巴胺突触后受体介导的高运动性，表明它不干扰α-2 去甲肾上腺素能和多巴胺突触后受体的功能。
